Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA: The Antidote to Anecdotal Safety Challenges

This article was originally published in RPM Report

Executive Summary

The Food & Drug Administration's role as the expert arbiter of drug safety issues is traditionally viewed as a threat to commercial products. But the agency also serves as an important protector of companies and products from unverified allegations of safety problems with marketed products or products in development. An important regional biotech trade group, BayBio, focuses on the role of FDA as impartial judge of the importance of clinical reports in a recent filing with the Supreme Court.

You may also be interested in...



US FDA Thinking Small To Solve Big Shortages

FDA is joining the government’s bioresponse and defense efforts to develop small, mobile, on-demand manufacturing systems as next-tech solutions to dwindling domestic supply sources for essential drugs.

'Dear Doctor Mom' – US FDA Urged To Find Way To Reach Pediatric Patient Parents With Safety Updates

How should FDA make sure new safety information gets widely disseminated – especially against a history of many communications that have not shown the sustained ability to reach the most active prescribers? The agency got an earful of suggestions from the most recent safety review of the asthma/allergy drug montelukast.

Patent “March-In” As Price Control Draw Little Support At US National Academies Meeting

The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.

Topics

Related Companies

UsernamePublicRestriction

Register

PS080735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel